Respirion Pharmaceuticals
Respirion Pharmaceuticals is an early-stage biotechnology company founded in 2018, focused on developing new treatments for respiratory diseases, particularly Cystic Fibrosis. The company is a spinout from the Telethon Kids Institute in Perth and has partnered with major investment and research organizations to conduct clinical trials. Their lead product is an inhaled therapy combining a widely used antibiotic with a biofilm disrupting agent, showing promising results in early studies.
Industries
Nr. of Employees
small (1-50)
Respirion Pharmaceuticals
Patents
Products
Inhaled combination therapy for cystic fibrosis
A nebulized combination therapy comprising a clinically used antibiotic paired with a biofilm-disrupting agent, formulated for aerosol delivery to the lung; demonstrated in an initial human pilot study to improve bacterial clearance and lung function and currently under further clinical evaluation.
Inhaled combination therapy for cystic fibrosis
A nebulized combination therapy comprising a clinically used antibiotic paired with a biofilm-disrupting agent, formulated for aerosol delivery to the lung; demonstrated in an initial human pilot study to improve bacterial clearance and lung function and currently under further clinical evaluation.
Services
Support for planning and executing clinical studies for inhaled respiratory therapies, including partnerships with academic and public health institutions.
Development of inhalation-ready formulations and CMC activities for nebulized therapeutics, including scale-up considerations for clinical use.
Regulatory planning and submissions support for complex drug-device and combination inhaled therapies across international jurisdictions.
Design and interpretation of preclinical inhalation toxicology studies and safety assessments to support clinical entry of inhaled therapeutics.
Support for planning and executing clinical studies for inhaled respiratory therapies, including partnerships with academic and public health institutions.
Development of inhalation-ready formulations and CMC activities for nebulized therapeutics, including scale-up considerations for clinical use.
Regulatory planning and submissions support for complex drug-device and combination inhaled therapies across international jurisdictions.
Design and interpretation of preclinical inhalation toxicology studies and safety assessments to support clinical entry of inhaled therapeutics.
Expertise Areas
- Clinical trial management for inhaled therapies
- Inhalation drug formulation and CMC
- Aerosol delivery and nebulizer optimization
- Inhalation toxicology and preclinical safety
Key Technologies
- Inhaled combination antibiotic therapy
- Biofilm-disrupting adjuvants
- Vibrating mesh nebulizer aerosol delivery
- Nebulized drug formulation
News & Updates
An international clinical trial is underway on a Western Australian-developed inhaled antibiotic combination for people with cystic fibrosis. A preliminary clinical study showed the treatment is effective in reducing infection and improving lung function.
Respirion’s technology was featured on Channel 9 News on 12 May 2024, sharing a story of a 17-year-old with Cystic Fibrosis and the potential impact of their technology.
An article published in the Journal of Cystic Fibrosis on 16 December 2020 discusses a clinical trial involving Tris-CaEDTA as an adjuvant with nebulised tobramycin for CF patients with Pseudomonas aeruginosa lung infections.
Respirion was selected for a grant supporting early-stage translation and commercialization efforts.
An international clinical trial is underway on a Western Australian-developed inhaled antibiotic combination for people with cystic fibrosis. A preliminary clinical study showed the treatment is effective in reducing infection and improving lung function.
Respirion’s technology was featured on Channel 9 News on 12 May 2024, sharing a story of a 17-year-old with Cystic Fibrosis and the potential impact of their technology.
An article published in the Journal of Cystic Fibrosis on 16 December 2020 discusses a clinical trial involving Tris-CaEDTA as an adjuvant with nebulised tobramycin for CF patients with Pseudomonas aeruginosa lung infections.
Respirion was selected for a grant supporting early-stage translation and commercialization efforts.